Endothelial dysfunction occurs in chronic kidney disease (CKD) and increases the risk for cardiovascular disease. The mechanisms of endothelial dysfunction seem to evolve throughout kidney disease progression, culminating in reduced L-arginine transport and impaired nitric oxide bioavailability in advanced disease. This review examines the hypothesis that aerobic exercise may reverse endothelial dysfunction by improving endothelial cell L-arginine uptake in CKD.
INTRODUCTION
Chronic kidney disease (CKD) is a major public health concern that results in progressive and irreversible loss of renal function and a concomitant increase in cardiovascular disease (CVD)Yrelated mortality that accounts for more than half of all deaths in patients with CKD (38) . Importantly, the increased incidence of CVD with CKD persists even in the absence of traditional CVD risk factors, suggesting that the mechanisms involved are unique to CKD. Vascular endothelial dysfunction is emerging as an important mediator and ''nontraditional'' risk factor in the development of CVD and, thus, is an attractive target for interventions designed to reduce the risk and burden of CVD in patients with CKD (21) . The mechanisms by which endothelial dysfunction occurs in CKD are multifaceted and seem to evolve throughout the progression of the disease. The early mechanisms likely involve a reduction in nitric oxide (NO) synthesis and bioavailability that is largely the result of oxidative stress and endogenous inhibition of endothelial NO synthase (eNOS) (21) . Limited but compelling evidence suggests that these mechanisms become less reversible in later stages of CKD because of an overwhelming reduction in the endothelial cell uptake of L-arginine, the critical substrate for NO synthesis (2, 22, 36) .
Superimposed on the cardiovascular consequences of CKD is a reduction in cardiorespiratory fitness and physical function that occurs during the initial stages of CKD and continues throughout disease progression (14, 27) . Physical deconditioning and CVD are linked in CKD; patients with a lower cardiorespiratory fitness exhibit a higher CVD burden (13) . Factors associated with both CKD and CVD exacerbate the decline in cardiorespiratory fitness, leading to a downward spiral of physical inactivity, deconditioning, and frailty that ultimately leads to decreased quality of life, increased hospitalization, and increased mortality rates ( Fig. 1) . Thus, interventions that increase physical activity and maintain cardiorespiratory fitness and physical function may be important for improving quality of life and reducing CVD mortality risk in CKD (16) . Aerobic exercise training is an important intervention for modifying traditional CVD risk factors but also may improve endothelial function in CKD.
Regular aerobic exercise is a well-established stimulus for improving NO synthesis and, therefore, is an important ''nonpharmacological'' strategy for improving cardiorespiratory fitness and improving endothelial function in patients with CVD. Although previous findings consistently have reported increases in cardiorespiratory fitness with regular exercise in the CKD population (16) , investigations determining the effects of regular aerobic exercise on endothelial function and the related mechanisms specific to CKD remain scarce. The mechanisms by which endothelial dysfunction occurs with advancing CKD may limit the efficacy of strategies such as antioxidant and L-arginine supplementation but may be susceptible to modification by aerobic exercise training. We propose a novel hypothesis by which regular aerobic exercise may reverse endothelial dysfunction by improving endothelial cell L-arginine uptake in CKD; thus, aerobic exercise training could represent a novel adjunctive therapy for lowering the burden of CVD and improving cardiorespiratory fitness across all stages of CKD. This article will focus primarily on the mechanisms of endothelial dysfunction in CKD and will introduce the novel mechanisms by which exercise might improve endothelial function in patients with CKD.
ENDOTHELIAL DYSFUNCTION
The vascular endothelium is a single monolayer of cells lining the interior lumen of all blood vessels. Among the many important functions of the endothelium are the synthesis and release of the vascular protective and vasodilatory molecule nitric oxide (NO), which maintains homeostasis within blood vessels by regulating leukocyte adhesion and infiltration, smooth muscle proliferation, inflammation, and vascular tone. Endothelium-derived NO is synthesized from the amino acid L-arginine by the enzyme eNOS and diffuses into the surrounding vascular smooth muscle where it initiates a signaling cascade that ultimately results in smooth muscle relaxation and vasodilation. Endothelial dysfunction is typically characterized by a reduction in endotheliumdependent vasodilation primarily because of a decline in endothelium-derived NO synthesis and/or bioavailability. Forearm reactive hyperemia, a measure of microvascular vasodilation that is mediated in part by NO production, is impaired in patients with end-stage renal disease and is directly associated with increased mortality risk (20) . Endothelial dysfunction also occurs in patients with more moderate CKD (18), suggesting that impairments in endothelial function serve as a key intermediary event linking CKD to increased CVD risk. Indeed, endothelial dysfunction has been shown to precede the development of atherosclerosis, and impairments in NO signaling have been linked to cardiac dysfunction (17) , implicating a dysfunctional endothelium as a key mediator in the pathogenesis of ischemic heart disease. Consequently, patients with CKD are more likely to die from CVD than to progress to end-stage renal disease (10) . Thus, therapies aimed at improving endothelial function hold great promise for reducing the burden of CVD in patients with CKD.
MECHANISMS OF ENDOTHELIAL DYSFUNCTION IN CKD
Endothelial dysfunction is evident in patients with moderateto-severe CKD (18) and can be modeled in rodents that have undergone surgical renal mass reduction or infarction (12, 22) . The specific mechanisms by which endothelial dysfunction occur in CKD are not completely understood; however, limited evidence from animal models and human studies points to reduced NO synthesis and/or bioavailability secondary to oxidative stress and a disruption in the synthesis, delivery, and utilization of L-arginine, the primary substrate for NO synthesis. The relative contribution of these mechanisms seems to change throughout the progression of CKD culminating in endothelial dysfunction that is less reversible under severe uremic conditions ( Fig. 2 ). These mechanisms are reviewed below.
Oxidative Stress
Oxidative stress is characterized by a disproportionate increase in cellular reactive oxygen species (ROS) relative to endogenous antioxidant defenses and is a key mechanism in the early pathogenesis of endothelial dysfunction in patients with mild-to-moderate CKD. Our laboratory has used laser Doppler flowmetry in the human skin microvasculature (a representative model of systemic microcirculatory function) coupled with intradermal microdialysis to determine the role of oxidative stress in endothelial dysfunction of patients with mild-to-moderate CKD (8, 9) . Local heating of the skin results in a vasodilatory response and marked increase in blood flow within the cutaneous circulation that is mediated primarily by an increase in NO synthesis. Compared with healthy age-matched control subjects, this measure of microcirculatory function is attenuated in patients with stage 3Y4 CKD; however, acute local infusion of the nonspecific antioxidant ascorbic acid within the cutaneous microvasculature ameliorates the impaired dilatory response in CKD patients to levels that resemble healthy control subjects, suggesting that excess ROS contributes to the suppression of vascular function in CKD (8) . Pathological levels of the free radical superoxide (O 2 j ) are capable of rapidly reacting with NO to form the secondary radical peroxynitrite (ONOO j ), reducing the overall bioavailability of NO available for vasodilation. This mechanism seems to contribute to the oxidative stress-mediated suppression of endothelial function in CKD, as local infusion of the skin microvasculature with the superoxide dismutase mimetic Tempol restores microvascular function in patients with CKD (9) .
Elevated levels of ROS have been shown to oxidize the essential eNOS cofactor, tetrahydrobiopterin (BH 4 ). Not only does this result in destabilization and uncoupling of the eNOS dimer but also can convert eNOS itself into a generator of superoxide, further perpetuating oxidative stress within the endothelium. Chronic supplementation with exogenous BH 4 has been shown to prevent eNOS uncoupling and preserve endothelium-dependent relaxation in rats with CKD (40); however, a recent clinical trial with the oral drug sapropterin (a synthetic form of BH 4 ) failed to demonstrate similar improvements in patients with CKD (28), thus, the role of reduced BH 4 in mediating oxidative stress and endothelial dysfunction in CKD remains inconclusive.
One potential therapeutic approach to combat vascular oxidative stress is to target the cellular sources of superoxide production. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidases have been identified as a major enzymatic source of superoxide generation and likely play a role in endothelial dysfunction in CKD. Our laboratory has recently demonstrated that acute local infusion of the NADPH oxidase inhibitor apocynin restores NO-mediated vasodilation in the skin microvasculature (9) . The mechanisms by which NADPH oxidases are activated in CKD are not known completely; however, angiotensin II has been shown to increase superoxide production through activation of NADPH oxidases (11) and may be an important contributor to oxidative stress in CKD. In support of this hypothesis, short-term angiotensin-converting enzyme inhibition has been shown to improve endothelial function in humans with stage 1 diabetic CKD (41) . Thus, interventions that target the cellular sources of superoxide production within the endothelium have the potential to improve endothelial function and reduce CVD risk in patients with CKD.
Endogenous NO Inhibition by Asymmetric Dimethylarginine
In addition to oxidative stress, increased formation of the endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) is associated independently with CVD risk in patients with CKD (21) . ADMA is produced as the result of posttranscriptional methylation of L-arginine residues within proteins by arginine methyltransferase enzymes (PRMT) and is released in its free form after protein hydrolysis. The chemical structure of ADMA is close enough to that of L-arginine that it prevents NO production through competitive inhibition of eNOS. ADMA is elevated in patients with stage 3Y4 CKD who exhibit endothelial dysfunction (8) , and elevated ADMA contributes to a reduction in the L-arginine/ADMA ratio (9), suggesting a relative reduction in L-arginine availability for NO production in CKD. Local infusion with exogenous Larginine in patients with mild-to-moderate CKD restores NOmediated vasodilation to levels of healthy control subjects (8) presumably by restoring the levels of L-arginine relative to increased ADMA. The clearance of ADMA by the kidney is impaired in CKD and contributes to elevated plasma concentrations; however, elevated ADMA in CKD is not explained by impaired urinary clearance alone (2) and likely is associated with increased ADMA synthesis. The mechanism by which ADMA formation is increased in CKD is likely related to increased expression and activity of PRMT and reduced degradation of ADMA by dimethylarginine dimethylaminohydrolase (2) . PRMT expression is elevated in an animal model of CKD (24) and may be a potential therapeutic target to restore endothelial function in humans. PRMT expression and activity are increased in the presence of oxidized low-density lipoprotein cholesterol and results in increased production of ADMA in endothelial cells (2), suggesting a potentiation of ADMA formation by oxidative stress in CKD. Treatment with exogenous antioxidants has been shown to reduce ADMA levels in patients with CKD and in patients on hemodialysis (35) and may be an effective strategy for restoring endothelial function in CKD. In addition, suppression of the renin-angiotensin system with short-term angiotensinconverting enzyme inhibition or angiotensin II receptor inhibition has been shown to reduce ADMA levels and improve flow-mediated dilation in patients with nondiabetic CKD (41) .
Impaired L-arginine Availability
Although the intracellular concentration of L-arginine typically exceeds what is necessary for NO synthesis, treatment with exogenous L-arginine has repeatedly been shown to augment NO production in a variety of clinical pathologies (5, 6, 31) . This phenomenon is referred to as the ''L-arginine Paradox'' and suggests that NO production relies, at least in part, on an adequate supply of extracellular L-arginine. Decreases in the availability, production, or delivery of L-arginine all seem to play important roles in the pathogenesis of endothelial dysfunction in CKD; however, the relative contributions of these mechanisms seem to be different throughout disease progression.
L-arginine is a semiessential amino acid that can be either obtained through dietary sources or synthesized by the proximal tubule cells of the kidney. In addition to acting as a substrate for NO synthesis, L-arginine also is metabolized by the enzyme arginase as part of the urea cycle. Increased arginase activity is thought to contribute to endothelial dysfunction in CVD through competition with eNOS for L-arginine. Systemic arginase inhibition slows the early progression of renal dysfunction in animals with CKD (4); however, vascular arginase expression and activity do not seem to be elevated once renal dysfunction is established (4, 22) and arginase inhibition does not reverse endothelial dysfunction in animals with more advanced CKD (22) . The accumulation of circulating urea that results from impaired renal function may act in a negative-feedback manner to suppress the urea cycle, including arginase activity. This has been demonstrated in the liver of animals with CKD (26) and also may explain why arginase does not contribute to endothelial dysfunction during later stages of CKD.
An alternative mechanism by which impaired L-arginine availability may occur in CKD is through decreased synthesis. L-arginine is synthesized from the precursor, L-citrulline, in the proximal tubule cells of the kidney (3). Protein expression of the key enzymes responsible for L-arginine synthesis is diminished in the kidneys of animals with CKD and plasma levels of L-citrulline levels are elevated, suggesting less conversion of L-citrulline to L-arginine (3) . To compensate for the decrease in endogenous L-arginine synthesis, treatment with exogenous L-arginine has been explored in the context of endothelial function; however, this approach has been met with mixed results. Dietary supplementation with L-arginine has been shown to prevent the development of endothelial dysfunction in an animal model of CKD when initiated immediately after disease induction (40) ; however, we have demonstrated recently that oral supplementation with L-arginine does not reverse endothelial dysfunction in animals once CKD has been already established (23) . These findings are mirrored by acute infusion studies in humans in which exogenous L-arginine improved vasodilation in the skin microvasculature of patients with moderate CKD (8) but did not restore endothelial function in the forearm microvasculature of patients with severe renal failure (7) . Much like the role of arginase, the ability of exogenous L-arginine to compensate for reduced L-arginine availability seems to be diminished by the progression of CKD and limits its ability to restore endothelial function.
A key mechanism that may explain why L-arginine is effective in earlier stages of CKD but is less effective during advanced disease progression is impaired cellular uptake of L-arginine. The plasma concentration of L-arginine is paradoxically maintained in patients with CKD, despite a decrease in endogenous production suggesting that plasma L-arginine may become ''trapped'' within the vascular space at some point throughout the disease progression. The uptake of L-arginine into cells, including endothelial cells, occurs through the cationic amino acid transporter CAT-1 and has been shown to be impaired in endothelial cells cultured in uremic plasma (2) . CAT-1 colocalizes with eNOS within the endothelial cell membrane (25) , creating a convenient mechanism by which L-arginine can be delivered directly to the endothelium to facilitate NO synthesis. Our laboratory and others have shown that the abundance and transport activity of CAT-1 within the vasculature are impaired in animal models of CKD (22, 36) and is likely an important contributor to endothelial dysfunction (22) . The mechanisms regulating the decrease in L-arginine transport in CKD have not been completely elucidated; however, the expression and activation of protein kinase C-> (PKC>) have been shown to occur within the vasculature of uremic rats and are associated with a reduction in CAT-1 transport activity (15) . The exact mechanisms by which PKC> attenuates L-arginine transport remain to be fully understood but seem to influence the subcellular localization of CAT-1 as activation of PKC> has been shown to promote the internalization of CAT-1 into the cytosol (34) . In addition, PKC> may exert direct effects on L-arginine transport via posttranslational phosphorylation of CAT-1 (15) . Taken together, these findings suggest that L-arginine transport can be altered via changes in both CAT-1 activity and protein abundance within the cell membrane. Treatments aimed at restoring CAT-1 expression and activity, therefore, may have a positive effect on vascular function by improving substrate delivery and NO production.
Endothelial Dysfunction in Advanced CKD: Evidence for a ''Uremic Switch''
The stimulus for decreased L-arginine transport seems to be related to an increase in circulating urea and other uremic toxins that occurs with CKD. CAT-1 transport activity has been shown to be inhibited in endothelial cells cultured in uremic plasma and in cells cultured in a synthetic solution containing uremic levels of urea (2) . The influx of extracellular urea through endothelial urea transporters (UT) prevents L-arginine transport in cells treated with high levels of urea (2) . Thus, the progressive increase in circulating urea and other uremic toxins that accompanies advancement of CKD may trigger a ''uremic switch'' that results in endothelial dysfunction that is less reversible by exogenous treatment with L-arginine because of inefficient transport through CAT-1 (Fig. 3) .
The point at which a uremic switch may occur during kidney disease progression is presently unknown; however, in addition to limiting the efficacy of L-arginine, the consequences seem to overshadow the contribution of other important mechanisms of endothelial dysfunction such as oxidative stress. Evidence for a uremic switch is supported by our own studies in which acute scavenging of superoxide with the antioxidant Tempol was unable to reverse endothelial dysfunction in isolated arteries from animals with advanced CKD that exhibited impaired L-arginine transport (22) as it did in our studies of patients with moderate CKD (9) . Collectively, studies in animal models and in patients with CKD suggest that oxidative stress, ADMA, and impaired L-arginine transport contribute to endothelial dysfunction that is increasingly less reversible by conventional approaches as the disease progresses. As such, there is a critical need for interventions that target these mechanisms and reduce CVD risk in patients with CKD.
EXERCISE AND ENDOTHELIAL FUNCTION IN CKD
Aerobic exercise is a well-known stimulus for improving endothelial function in CVD, and limited but compelling evidence from animal studies suggests that exercise may have similar beneficial effects on endothelial function in CKD (1, 23, 37) . The mechanisms by which aerobic exercise training improves endothelial function in CVD are multifaceted but are associated largely with an increase in endothelial NO bioavailability. Recent evidence from our own work supports the novel hypothesis that aerobic exercise training improves endothelial function in CKD by reversing impairments to the L-arginine transport system, facilitating substrate delivery for NO production (23) . Because of the body of literature suggesting that endothelial dysfunction becomes increasingly more difficult to reverse in advanced CKD, aerobic exercise training may represent a novel adjunctive therapy to treating endothelial dysfunction in CKD.
The Role of Shear Stress in L-arginine Transport
Aerobic exercise results in a systemic increase in blood flow that produces tangential and circumferential shear forces against the endothelial surface. Shear stress is the primary endogenous stimulus for endothelial NO production, which is largely attributable to increased eNOS expression and activation, and may be among the most important mechanisms by which regular aerobic exercise training improves endothelial function in CVD. Endothelial cell L-arginine uptake occurs in a stimulus-dependent manner in response to increasing levels of shear stress in cultured endothelial cells (32) . This mechanism likely plays an important role in maintaining endothelial function by ensuring that an appropriate supply of substrate is available for NO synthesis in response to increasing demands for blood flow. Importantly, shear stress-mediated NO production is attenuated when Larginine transport is impaired (32) , suggesting that CAT-1 may be important for transducing the effects of shear stress to increase NO synthesis. The ability of shear stress to augment L-arginine transport activity suggests that regular aerobic exercise training may be an effective therapy to counteract the impairments in L-arginine transport that occur with CKD. In support of this hypothesis, 8 wk of aerobic exercise training has been shown to improve L-arginine uptake by the forearm microvasculature in patients with congestive heart failure (29) . We recently have extended these findings to an animal model of CKD in which we demonstrated improved L-arginine transport activity in response to 8 wk of very low volume voluntary wheel running, a model of regular aerobic exercise training (23) .
The precise mechanism by which elevated shear stress increases L-arginine transport in CKD is not known. Evidence from our own work suggests that the increase in L-arginine transport by voluntary wheel running is not associated with an increase in CAT-1 abundance but rather through an increase in L-arginine transport activity (23) . Thus, the regulation of L-arginine transport by aerobic exercise training likely occurs at the posttranslational level presumably through modification of CAT-1. One potential mechanism by which exercise may improve CAT-1 activity is through a decrease in Figure 3 . The mechanisms of endothelial dysfunction seem to change throughout the progression of chronic kidney disease (CKD), resulting in endothelial dysfunction that is increasingly less reversible. Competition for L-arginine by the enzyme arginase may play a limited role in early CKD but seems to play less of a role throughout disease progression. Oxidative stress and increased levels of asymmetric dimethylarginine (ADMA) are important contributors to endothelial dysfunction in mild-to-moderate CKD. The accumulation of uremic toxins that occurs throughout the progression of CKD contributes to impaired transport of L-arginine into the endothelium. During advanced stages of CKD, this uremic toxin burden becomes so severe that a ' 'uremic switch' ' occurs in which reduced L-arginine transport becomes the rate-limiting step for nitric oxide production.
the expression or activity of PKC>. As mentioned previously, vascular PKC> expression is increased in CKD and is thought to play a role in the posttranslational regulation of L-arginine transport via direct phosphorylation and/or by promoting the internalization of CAT-1 to the cytosol. Our recent work demonstrated that 4 wk of voluntary wheel running reverses the increase in aortic PKC> protein expression that occurs with CKD and that this is associated with a robust increase in L-arginine transport activity, independent of changes in total aortic CAT-1 abundance (23) . Thus, we propose a novel hypothesis by which aerobic exercise may target the vascular endothelium in CKD and augment endothelial cell L-arginine transport by reducing PKC> expression, ultimately resulting in improved endothelial function ( Fig. 4) . Future work is necessary to determine whether this mechanism increases L-arginine transport predominantly by increasing CAT-1 transport activity or by maintaining the abundance of CAT-1 within the endothelial cell membrane.
Flipping the Switch: Exercise and L-arginine to Improve Endothelial Function in CKD
The ability of exogenous L-arginine to augment NO production, despite a seemingly sufficient intracellular concentration, long has been a topic of interest in vascular physiology. The fact that this phenomenon seems to be absent in patients and animals with advanced CKD provides a unique window into the role of the ''L-arginine Paradox'' in CKD. The finding that exercise improves L-arginine transport in CKD demonstrates the potential benefit of increased physical activity on vascular function in CKD; however, the association between exercise and L-arginine transport may be exploited most effectively when exercise and L-arginine are used in combination. We have demonstrated recently that dietary supplementation with L-arginine alone does not reverse endothelial dysfunction in rats with CKD presumably because of impaired L-arginine transport activity (23) . Importantly, wheel running significantly improved L-arginine transport activity and augmented NO-dependent endothelial function; however, the greatest improvement was seen when voluntary wheel running and L-arginine supplementation were combined (Fig. 5 ). These findings suggest that although L-arginine itself may not be an effective therapy to . Endothelial function is impaired in rats with chronic kidney disease (CKD) relative to sham control rats. Supplementation with L-arginine alone does not improve endothelium-dependent relaxation (EDR); however, 4 wk of aerobic exercise (through voluntary wheel running) improves EDR in rats with CKD, and the greatest benefit is observed when aerobic exercise and L-arginine supplementation are performed in combination. Data represent the area under the dose-response curve of EDR in response to increasing doses of the endothelium-dependent vasodilator acetylcholine. *P G 0.05 versus sham; #P G 0.05 versus CKD; †P G 0.05 treat vascular dysfunction in CKD, aerobic exercise may be capable of overcoming the ''uremic switch,'' thus, facilitating improved delivery and utilization of L-arginine. The use of aerobic exercise to flip the uremic switch may increase the efficacy of L-arginine supplementation for improving endothelial function in CKD.
Reversing the impairment in endothelial L-arginine transport also may lead to direct improvements in cardiac function presumably through increased NO production within coronary arteries. In support of this hypothesis, endothelialspecific overexpression of CAT-1 recently has been reported to prevent pressure overload-induced cardiac hypertrophy in mice (33) , and we recently have demonstrated preserved cardiac function in a rodent model of CKD subjected to 4 wk of voluntary wheel running (19) . Although the combined effect of exercise and L-arginine supplementation on cardiac function in CKD has not yet been tested, these findings collectively suggest that aerobic exercise and sufficient endothelial L-arginine transport are important for the maintenance of cardiac function. Improved L-arginine transport and utilization by the endothelium would be particularly beneficial to patients with CKD, and exercise might be a novel therapeutic approach to treat endothelial dysfunction and reduce CVD risk in CKD.
SUMMARY AND PERSPECTIVES
In summary, CVD remains the leading cause of death in CKD, with patients more likely to die from CVD than progress to end-stage renal failure. Endothelial dysfunction is characteristic of CKD and is thought to be a major nontraditional risk factor mediating the CVD burden in CKD. As renal function worsens with progression of CKD, the mechanisms of endothelial dysfunction seem to change and conventional therapies to restore endothelial health become less effective. Although oxidative stress and increased levels of ADMA contribute to impaired NO production and bioavailability in the earlier stages of CKD, reduced endothelial transport of L-arginine seems to be a limiting factor for NO production in severe CKD. Recent findings from our laboratory demonstrate that L-arginine uptake is increased after relatively low volumes of aerobic exercise in an animal model of severe CKD, improving the efficacy of L-arginine supplementation. Although the mechanisms remain to be elucidated fully, it is hypothesized that exercise-induced endothelial shear stress prevents the phosphorylation and internalization of the L-arginine transporter CAT-1, maintaining adequate L-arginine delivery for NO production.
Despite the benefits of aerobic exercise training on L-arginine transport, NO production, and overall vascular function in animal models, the influence of exercise training on vascular function in humans with CKD is less established (16) . To date, the only known trial to investigate the effects of aerobic exercise on endothelial function showed no significant improvements; however, the exercise intervention consisted of a low-volume, intermittent, home-based training program that may not have provided an adequate stimulus to reverse endothelial dysfunction (39) . Although moderate-intensity aerobic exercise training does seem to positively influence some known mediators of endothelial dysfunction such as oxidative stress in CKD patients (30) , there is a need for more randomized controlled trials investigating the effects of aerobic exercise on vascular health in CKD patients to ascertain the most effective exercise doses and guide evidencebased exercise prescription. In addition, further research is needed to determine whether the mechanisms by which aerobic exercise improves endothelial function in animal models of CKD translate to CKD patients. The novel mechanisms by which aerobic exercise targets the vascular endothelium in animal models of CKD provide a strong rationale for translational investigations in human patients. Regular aerobic exercise has the potential to serve as an important adjunctive therapy in patients with CKD to ameliorate endothelial dysfunction and reduce the high risk of CVD, making this an important area for future research.
